Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Keros Therapeutics Inc’s stock clocked out at $14.49, down -0.21% from its previous closing price of $14.52. In other words, the price has decreased by -$0.21 from its previous closing price. On the day, 0.52 million shares were traded. KROS stock price reached its highest trading level at $14.66 during the session, while it also had its lowest trading level at $14.255.
Ratios:
To gain a deeper understanding of KROS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.09. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Wedbush Downgraded its Outperform to Neutral on January 17, 2025, while the target price for the stock was maintained at $15.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 09 ’25 when ADAR1 Capital Management, LLC bought 934,258 shares for $10.13 per share. The transaction valued at 9,464,512 led to the insider holds 4,392,737 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 588517120 and an Enterprise Value of -82525192. As of this moment, Keros’s Price-to-Earnings (P/E) ratio for their current fiscal year is 46.25. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 14.97. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.53 while its Price-to-Book (P/B) ratio in mrq is 0.83. Its current Enterprise Value per Revenue stands at -0.354 whereas that against EBITDA is -49.357.
Stock Price History:
The Beta on a monthly basis for KROS is 1.06, which has changed by -0.691308 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is 3.66%, while the 200-Day Moving Average is calculated to be -29.19%.
Shares Statistics:
It appears that KROS traded 522.54K shares on average per day over the past three months and 464660 shares per day over the past ten days. A total of 40.62M shares are outstanding, with a floating share count of 33.98M. Insiders hold about 16.33% of the company’s shares, while institutions hold 87.30% stake in the company. Shares short for KROS as of 1753920000 were 4841195 with a Short Ratio of 9.26, compared to 1751241600 on 5164330. Therefore, it implies a Short% of Shares Outstanding of 4841195 and a Short% of Float of 18.67.
Earnings Estimates
At present, 7.0 analysts are actively evaluating the performance of Keros Therapeutics Inc (KROS) in the stock market.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.29 and low estimates of -$1.63.
Analysts are recommending an EPS of between $2.46 and -$0.21 for the fiscal current year, implying an average EPS of $0.97. EPS for the following year is -$3.98, with 8.0 analysts recommending between -$0.75 and -$5.81.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for KROS’s current fiscal year. The highest revenue estimate was $250M, while the lowest revenue estimate was $220M, resulting in an average revenue estimate of $235.83M. In the same quarter a year ago, actual revenue was $3.55M
